CTLA4 and neoplasm: Recent work has demonstrated that combinatorial treatment with anti-CTLA-4 antibodies and low-dose AZA or DAC results in significantly decreased tumor growth of melanoma cells in a murine xenograft setting, compared with CTLA-4 therapy alone [92].